These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27146194)

  • 1. Gadolinium-based Contrast Agents: Patient Safety Concerns.
    Foster-Bollman C; Mackey TK
    Radiol Technol; 2016 May; 87(5):552M-6M. PubMed ID: 27146194
    [No Abstract]   [Full Text] [Related]  

  • 2. Nephrogenic systemic fibrosis: the story unfolds.
    Prchal D; Holmes DT; Levin A
    Kidney Int; 2008 Jun; 73(12):1335-7. PubMed ID: 18516057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can gadolinium be safely given in renal failure?
    Weissleder R
    AJR Am J Roentgenol; 1996 Jul; 167(1):278-9. PubMed ID: 8659405
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk of acute kidney injury after exposure to gadolinium-based contrast in patients with renal impairment.
    Chien CC; Wang HY; Wang JJ; Kan WC; Chien TW; Lin CY; Su SB
    Ren Fail; 2011; 33(8):758-64. PubMed ID: 21777176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Renal toxicity of contrast agents in oncologic patients].
    Amet S; Deray G
    Bull Cancer; 2012 Mar; 99(3):295-307. PubMed ID: 22082610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute renal failure after arteriography with a gadolinium-based contrast agent.
    Gemery J; Idelson B; Reid S; Yucel EK; Pagan-Marin H; Ali S; Casserly L
    AJR Am J Roentgenol; 1998 Nov; 171(5):1277-8. PubMed ID: 9798860
    [No Abstract]   [Full Text] [Related]  

  • 7. Imaging patients with kidney disease: how do we approach contrast-related toxicity?
    Perazella MA; Reilly RF
    Am J Med Sci; 2011 Mar; 341(3):215-21. PubMed ID: 21139495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of nephrogenic systemic fibrosis.
    Daftari Besheli L; Aran S; Shaqdan K; Kay J; Abujudeh H
    Clin Radiol; 2014 Jul; 69(7):661-8. PubMed ID: 24582176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the potential causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis.
    Partain CL
    J Magn Reson Imaging; 2007 May; 25(5):879-80. PubMed ID: 17457806
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety of magnetic resonance contrast media: a review with special focus on nephrogenic systemic fibrosis.
    Haneder S; Kucharczyk W; Schoenberg SO; Michaely HJ
    Top Magn Reson Imaging; 2015 Feb; 24(1):57-65. PubMed ID: 25654421
    [No Abstract]   [Full Text] [Related]  

  • 11. Gadolinium-based percutaneous coronary intervention in a patient with renal insufficiency.
    Bokhari SW; Wen YH; Winters RJ
    Catheter Cardiovasc Interv; 2003 Mar; 58(3):358-61. PubMed ID: 12594702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States.
    Thomsen HS
    Radiol Clin North Am; 2009 Sep; 47(5):871-5, vii. PubMed ID: 19744601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NSF: still relevant.
    Thomsen HS
    J Magn Reson Imaging; 2014 Jul; 40(1):11-2. PubMed ID: 24990765
    [No Abstract]   [Full Text] [Related]  

  • 14. Gadolinium and nephrogenic systemic fibrosis: association or causation.
    Kurtkoti J; Snow T; Hiremagalur B
    Nephrology (Carlton); 2008 Jun; 13(3):235-41. PubMed ID: 18221255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of magnetic resonance contrast media.
    Runge VM
    Top Magn Reson Imaging; 2001 Aug; 12(4):309-14. PubMed ID: 11687717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of contrast-induced acute kidney injury.
    Malik A
    Br J Hosp Med (Lond); 2015 Dec; 76(12):685-9. PubMed ID: 26646329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis.
    Kuo PH; Kanal E; Abu-Alfa AK; Cowper SE
    Radiology; 2007 Mar; 242(3):647-9. PubMed ID: 17213364
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety update on the possible causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis.
    Pedersen M
    J Magn Reson Imaging; 2007 May; 25(5):881-3. PubMed ID: 17457808
    [No Abstract]   [Full Text] [Related]  

  • 19. Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis.
    Heverhagen JT; Krombach GA; Gizewski E
    Rofo; 2014 Jul; 186(7):661-9. PubMed ID: 24477507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephrogenic systemic fibrosis and gadolinium-enhanced magnetic resonance imaging: does a US Food and Drug Administration alert influence practice patterns in CKD?
    Martin DR
    Am J Kidney Dis; 2010 Sep; 56(3):427-30. PubMed ID: 20728788
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.